Myomo transferred with a Buy at Alliance Global Partners

Alliance Global Partners analyst Scott Henry took over coverage of Myomo with a Buy rating and a $4.75 price target. The company is positioned to capitalize on the expanding market for robotic solutions to upper extremity partial paralysis, says the analyst, who believes that an improving reimbursement environment, combined with expanded capacity, could drive significant upside to current revenues and “turn operations breakeven.”